214 related articles for article (PubMed ID: 15917651)
1. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.
Dhanabal M; Wu F; Alvarez E; McQueeney KD; Jeffers M; MacDougall J; Boldog FL; Hackett C; Shenoy S; Khramtsov N; Weiner J; Lichenstein HS; LaRochelle WJ
Cancer Biol Ther; 2005 Jun; 4(6):659-68. PubMed ID: 15917651
[TBL] [Abstract][Full Text] [Related]
2. Semaphorin-3F is an inhibitor of tumor angiogenesis.
Kessler O; Shraga-Heled N; Lange T; Gutmann-Raviv N; Sabo E; Baruch L; Machluf M; Neufeld G
Cancer Res; 2004 Feb; 64(3):1008-15. PubMed ID: 14871832
[TBL] [Abstract][Full Text] [Related]
3. Semaphorin 3C regulates endothelial cell function by increasing integrin activity.
Banu N; Teichman J; Dunlap-Brown M; Villegas G; Tufro A
FASEB J; 2006 Oct; 20(12):2150-2. PubMed ID: 16940438
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
5. 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.
Pang X; Zhang L; Lai L; Chen J; Wu Y; Yi Z; Zhang J; Qu W; Aggarwal BB; Liu M
Carcinogenesis; 2011 Jun; 32(6):904-12. PubMed ID: 21427164
[TBL] [Abstract][Full Text] [Related]
6. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Pan SL; Guh JH; Peng CY; Wang SW; Chang YL; Cheng FC; Chang JH; Kuo SC; Lee FY; Teng CM
J Pharmacol Exp Ther; 2005 Jul; 314(1):35-42. PubMed ID: 15784655
[TBL] [Abstract][Full Text] [Related]
7. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis.
Sulochana KN; Fan H; Jois S; Subramanian V; Sun F; Kini RM; Ge R
J Biol Chem; 2005 Jul; 280(30):27935-48. PubMed ID: 15923192
[TBL] [Abstract][Full Text] [Related]
8. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
9. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis.
Moriya J; Minamino T; Tateno K; Okada S; Uemura A; Shimizu I; Yokoyama M; Nojima A; Okada M; Koga H; Komuro I
Circ Res; 2010 Feb; 106(2):391-8. PubMed ID: 19940264
[TBL] [Abstract][Full Text] [Related]
11. Infantile hemangioma-derived stem cells and endothelial cells are inhibited by class 3 semaphorins.
Nakayama H; Huang L; Kelly RP; Oudenaarden CR; Dagher A; Hofmann NA; Moses MA; Bischoff J; Klagsbrun M
Biochem Biophys Res Commun; 2015 Aug; 464(1):126-32. PubMed ID: 26086095
[TBL] [Abstract][Full Text] [Related]
12. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
14. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
[TBL] [Abstract][Full Text] [Related]
17. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
18. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
[TBL] [Abstract][Full Text] [Related]
19. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
Chuang CH; Liu CH; Lu TJ; Hu ML
Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
[TBL] [Abstract][Full Text] [Related]
20. FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1.
Boosani CS; Nalabothula N; Munugalavadla V; Cosgrove D; Keshamoun VG; Sheibani N; Sudhakar A
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4567-75. PubMed ID: 19443723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
